Jun 28, 2026
15 MIN READ

Navigating Weight Loss: Understanding Who Shouldn’t Take Wegovy

Wegovy works for many people, but certain medical conditions and medications make it unsafe. PlexusDx offers personalized GLP-1 therapy options that may be right for you, with genetic testing to match your body's response.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 28, 2026
15 MIN READ

navigating weight loss: understanding who shouldn’t take wegovy — PlexusDx GLP-1 education

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (the active ingredient in Wegovy) is not appropriate for everyone. Approximately 1 in 4 people who start GLP-1 therapy stop due to side effects or medical contraindications, yet many never explore whether a different dose, formulation, or compound might work better for their specific health profile. Understanding who shouldn't take this medication—and why—helps you and your healthcare provider make safer, more informed decisions.

Medical Conditions That Contraindicate Wegovy Use

A personal or family history of medullary thyroid cancer (MTC) is an absolute contraindication to semaglutide. GLP-1 receptor agonists have been shown in animal models to increase C-cell proliferation in the thyroid, raising the theoretical risk of malignancy in humans. Patients with a genetic syndrome called multiple endocrine neoplasia type 2 (MEN-2) also cannot safely use this medication. Your healthcare provider should screen for these conditions before starting any GLP-1 therapy.

Severe pancreatitis or a history of acute pancreatitis requires careful evaluation. While the absolute causal link between GLP-1 drugs and pancreatitis remains debated, case reports and postmarketing surveillance have documented pancreatitis onset in some users. Patients with chronic pancreatitis or diabetic ketoacidosis (DKA) history should discuss alternatives with their doctor. PlexusDx's licensed compounding pharmacies work with providers to ensure medication selection aligns with your complete medical history.

Severe kidney disease (eGFR below 15 mL/min/1.73m²) may limit semaglutide safety due to accumulation risk. Patients on dialysis or with end-stage renal disease should have medication dosing and type carefully monitored. Similarly, active gallbladder disease or biliary obstruction creates additional metabolic stress that GLP-1 agents may worsen. A full renal and hepatic panel before starting treatment is essential.

Pregnancy, Breastfeeding, and Reproductive Considerations

Semaglutide is a pregnancy category C medication, meaning animal studies show potential fetal risk but human data remain limited. Women who are pregnant, attempting to become pregnant, or breastfeeding should not take Wegovy or other semaglutide formulations. The drug should be stopped at least 2 months before planned conception, as GLP-1 receptors play a role in early fetal development. Breastfeeding mothers should wait until lactation is complete, as semaglutide presence in breast milk has not been adequately studied.

Men seeking to father children may also benefit from pausing GLP-1 therapy, though data on male fertility impact are less extensive than female data. Rapid weight loss itself can temporarily affect sperm production and hormone levels. PlexusDx providers discuss family-planning timelines during the initial health assessment to ensure your weight loss plan aligns with reproductive goals.

Drug Interactions and Medication Conflicts

Semaglutide significantly slows gastric emptying, which can affect how your body absorbs other oral medications. Patients taking insulin or insulin secretagogues (like sulfonylureas) face increased hypoglycemia risk; dosing adjustments are mandatory and require close monitoring. Certain antibiotics, birth control pills, and blood pressure medications may have altered absorption rates when taken with semaglutide. Your pharmacist and provider must review your complete medication list before starting.

Patients on warfarin or other anticoagulants require special attention. Rapid weight loss from GLP-1 therapy can affect vitamin K absorption, potentially shifting INR (International Normalized Ratio) values and bleeding risk. Monthly INR monitoring may be needed during the initial treatment phase. PlexusDx's licensed compounding pharmacies coordinate with your prescribing physician to ensure safe medication timing and dose adjustments throughout your weight loss journey.

Understanding Your Genetic Response to GLP-1 Therapy

Not all weight loss failures mean semaglutide is wrong for you—sometimes it's the wrong dose, formulation, or even the wrong compound. Your genetic makeup influences how your body responds to GLP-1 receptor agonists. Four key genetic variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313) significantly affect treatment success. PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways and 150+ genetic insights to predict your peptide response before you commit to a therapy.

The PlexusDx approach differs from traditional Wegovy-only prescribing: if standard semaglutide isn't right for you—whether due to side effects, medical history, or genetics—alternatives exist. Compounded oral semaglutide, tirzepatide injection, oral tirzepatide, or dual-compound GLP-Squared protocols can be tailored to your biology. Your dose may need to go up. Your price won't—PlexusDx pricing remains flat across commitment tiers, starting at just $149/month for semaglutide injection.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy safe if I have type 2 diabetes and take insulin?

Wegovy can be used alongside insulin, but requires careful monitoring because GLP-1 drugs increase hypoglycemia risk. Your insulin dose will likely need to be reduced. Your prescriber must monitor blood glucose closely during the first weeks. If Wegovy's side effects feel too strong, PlexusDx offers alternative GLP-1 compounds and formulations that may work better for insulin-dependent diabetes.

Can I take Wegovy if I have a family history of thyroid cancer?

No—if you or a close family member have had medullary thyroid cancer or MEN-2 syndrome, semaglutide is contraindicated. However, this doesn't mean GLP-1 therapy is off the table. PlexusDx compounding pharmacies can discuss tirzepatide (a different GLP-1/GIP receptor agonist) or other weight loss approaches with your oncologist or endocrinologist.

What if I'm planning to get pregnant soon?

Semaglutide should be discontinued at least 2 months before attempting pregnancy. If you're considering starting weight loss therapy now, discuss your family-planning timeline with a PlexusDx provider. They can help you set realistic weight-loss milestones, plan when to pause treatment, and explore whether resuming after pregnancy aligns with your goals.

How much does PlexusDx semaglutide cost compared to Wegovy?

PlexusDx compounded semaglutide injection starts at $149/month—often significantly less than Wegovy's average $1,200+ monthly cost. No insurance required, no membership fee, and the price remains flat across all three commitment tiers. HSA and FSA plans are accepted, making weight loss more affordable and accessible.

Can genetic testing help me avoid side effects from Wegovy?

Yes. PlexusDx's Precision Peptide Genetic Test ($99 add-on after your first month) analyzes four key variants in GLP-1 and appetite-regulation pathways to predict your response. Testing helps your provider choose the right compound, formulation, and starting dose for your genetics—potentially reducing trial-and-error and unwanted effects before they happen.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves